{
    "root": "30dc8c36-63cc-07b4-e063-6294a90a9abb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Eprontia",
    "value": "20250321",
    "ingredients": [
        {
            "name": "POLYETHYLENE GLYCOL, UNSPECIFIED",
            "code": "3WJQ0SDW1A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "METHYLPARABEN",
            "code": "A2I8C7HI9T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_31835"
        },
        {
            "name": "PROPYLPARABEN",
            "code": "Z8IX2SC1OH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32063"
        },
        {
            "name": "SUCRALOSE",
            "code": "96K6UQ3ZD4",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32159"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB09462"
        },
        {
            "name": "TOPIRAMATE",
            "code": "0H73WJJ391",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63631"
        }
    ],
    "indications": {
        "text": "eprontia indicated : epilepsy : initial monotherapy treatment partial-onset primary generalized tonic-clonic seizures patients 2 years age older ( 1.1 ) ; adjunctive therapy treatment partial-onset seizures , primary generalized tonic-clonic seizures , seizures associated lennox-gastaut syndrome patients 2 years age older ( 1.2 ) . preventive treatment migraine patients 12 years age older ( 1.3 ) .",
        "doid_entities": [
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            },
            {
                "text": "lennox-gastaut syndrome (DOID:0050561)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0050561"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "migraine (DOID:6364)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6364"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "lennox-gastaut syndrome",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_2382"
            }
        ]
    },
    "contraindications": {
        "text": "eprontia initial dose , titration , recommended maintenance dose varies indication age group . full prescribing information recommended , dosing considerations patients renal impairment , geriatric patients , patients undergoing hemodialysis ( 2.1 , 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "eprontia oral solution 25 mg/ml supplied colorless slightly yellow colored clear viscous liquid white hdpe bottles . available follows : ndc size ndc 52652-9001-3 120 ml ndc 52652-9001-2 240 ml ndc 52652-9001-1 473 ml",
    "adverseReactions": "none .",
    "indications_original": "EPRONTIA is indicated for: Epilepsy: Initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older ( 1.1 ); adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older ( 1.2 ). Preventive treatment of migraine in patients 12 years of age and older ( 1.3 ).",
    "contraindications_original": "EPRONTIA initial dose, titration, and recommended maintenance dose varies by indication and age group. See Full Prescribing Information for recommended dosage, and dosing considerations in patients with renal impairment, geriatric patients, and patients undergoing hemodialysis ( 2.1 , 2.2 , 2.3 , 2.4 , 2.5 , 2.6 ).",
    "warningsAndPrecautions_original": "EPRONTIA oral solution 25 mg/mL is supplied as a colorless to slightly yellow colored clear viscous liquid in white HDPE bottles. It is available as follows:\n                        \n                           \n                           \n                           \n                              \n                                 \n                                    \n                                       NDC\n                                    \n                                 \n                                 \n                                    \n                                       Size\n                                    \n                                 \n                              \n                              \n                                 \n                                    NDC 52652-9001-3\n                                 \n                                 \n                                    120 mL\n                                 \n                              \n                              \n                                 \n                                    NDC 52652-9001-2\n                                 \n                                 \n                                    240 mL\n                                 \n                              \n                              \n                                 \n                                    NDC 52652-9001-1\n                                 \n                                 \n                                    473 mL",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "Eprontia",
            "drugbank_id": "https://go.drugbank.com/drugs/DB06405"
        }
    ]
}